(C) Our World in Data
This story was originally published by Our World in Data and is unaltered.
 . . . . . . . . . .



Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospect [1]

['Alison J Rodger', 'Alison.Rodger Ucl.Ac.Uk', 'Institute For Global Health', 'University College London', 'London', 'Valentina Cambiano', 'Tina Bruun', 'Department Of Infectious Diseases', 'Chip', 'Rigshospitalet']

Date: 2022-11 

The primary aim of the second phase of the PARTNER study (PARTNER2) was to produce a similar level of evidence for transmission risk through condomless anal sex between men with suppressive ART (defined as HIV-1 RNA viral load <200 copies per mL) to that generated for heterosexual couples in PARTNER1.

The Opposites Attract observational studyalso reported zero cases of HIV transmission in MSM couples during 232 couple-years of follow-up when condomless anal intercourse was reported, the HIV-positive partner was virally suppressed, and the HIV-negative partner did not use pre-exposure prophylaxis (PrEP), with a fairly high upper 95% CI limit of 1·59 per 100 couple-years of follow-up for transmission rate.

The first phase of the PARTNER study (PARTNER1) estimated the risks for different types of sex and in a broader population. The study reported no linked transmissions in 888 serodifferent couples (548 heterosexual and 340 gay couples) who reported condomless penetrative sex during 1238 couple-years of follow-up when the HIV-positive partner was on virally suppressive ART.PARTNER1 reported on 439 couple-years of follow-up in serodifferent gay couples, with zero transmissions reported. However, because of the lower number of couple-years of follow-up accumulated for gay couples than for heterosexual couples, the upper 95% CI limit for the transmission rate for gay men was relatively high (0·84 per 100 couple-years of follow-up), almost double that for heterosexual couples (0·46 per 100 couple-years of follow-up). These results equated to an upper limit of risk of one infection per 119 couple-years of follow-up for gay couples compared with one infection per 217 couple-years of follow-up for heterosexual couples and was arguably insufficient to provide the level of evidence required to support ART as a fully effective HIV prevention intervention in MSM.

The results from the PARTNER studies in addition to evidence from other studies in serodifferent couples indicate that the risk of transmission of HIV through condomless sex in the context of virally suppressive ART is effectively zero for both gay men and heterosexual couples. These results support the U=U (undetectable equals untransmittable) message, as well as promoting the benefits of early testing and treatment.

The second phase of the PARTNER study fills the gap in the evidence base for risk of HIV transmission in serodifferent gay couples in which the HIV-positive partner is on virally suppressive ART and condoms are not used. By the end of follow-up, 15 new HIV infections had occurred during eligible couple-years of follow-up, but none were phylogenetically linked within-couple transmissions. Thus, the linked HIV transmission rate during eligible couple-years was zero, despite 76 000 reports of condomless anal sex, with a low upper 95% CI limit of 0·23 per 100 couple-years of follow-up. Our findings provide a level of evidence on viral suppression and HIV transmission risk through condomless sex for gay men similar to that already reported for heterosexual couples.

To review previous evidence on the effect of antiretroviral therapy (ART) on risk of HIV transmission, we searched PubMed for articles published in English from Jan 1, 2000, to Nov 7, 2018, using the MeSH terms “HIV infection” and “transmission” and “antiretroviral therapy” or “ART” and “men who have sex with men” or “gay or heterosexual” or “serodiscordant” or “serodifferent”. Previous studies, including one randomised controlled trial and several observational studies, provided estimates of risk of HIV transmission through sexual intercourse in the context of virally suppressive ART. The bulk of the evidence was in heterosexual serodifferent couples and variable levels of condom use were reported in many studies. Some evidence on transmission risk in gay men was provided in the first phase of the PARTNER study and in the Opposites Attract study, but follow-up in these studies was not sufficient to exclude a significant upper limit of risk around the study estimates of zero transmissions in gay men.

Early evidence of a strong link between the HIV viral load of an HIV-positive partner and the risk of transmission to an HIV-negative partner came from observational studies in serodifferent heterosexual couples.Evidence from a randomised study of risk of HIV transmission in the context of virally suppressive antiretroviral therapy (ART) in heterosexual couples was provided by the HPTN 052 trial,which reported a 96% reduction in linked transmissions in couples assigned to early (immediate) ART compared with couples assigned to delayed therapy. Continued follow-up in HPTN 052 from 2011 to 2016, after all participants were offered ART, showed durability of the effect of ART; however, only 2% of couples were men who have sex with men (MSM).Self-reported condom use was also high; participants reported not using condoms for a total of only 63·4 couple-years of follow-up.

The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

In terms of sample size calculation, the PARTNER2 study was designed to assess whether the risk of transmission in the context of virally suppressive ART was below an acceptably low level, defined as one infection per 500 couple-years of follow-up, corresponding to an upper limit for the two-sided 95% CI of the rate of within-couple HIV transmission of 0·2 per 100 couple-years of follow-up. In the absence of linked infections, we determined that we needed 1770 eligible couple-years of follow-up to obtain such an upper limit of the two-sided 95% CI. On the basis of findings from PARTNER1, we planned to recruit 450 couples over 27 months in PARTNER2. Assuming a retention rate of 85%, this would have allowed us to accumulate 2082 couple-years of follow-up through PARTNER1 and PARTNER2, of which 85% were predicted to be eligible (based on interim results) for the primary analysis.

The primary analysis was estimation of the incidence rate of HIV transmission through condomless anal sex, calculated as the number of phylogenetically linked HIV infections (ie, transmission from the HIV-positive study index partner) that occurred during eligible couple-years of follow-up divided by eligible couple-years of follow-up. Couple-years of follow-up were periods of time defined by HIV tests and corresponding questionnaires on sexual behaviour in the HIV-negative partner. These couple-years were eligible for inclusion in the analysis for this study if couples had condomless sex during the period (reported at the end of the time period by the HIV-negative partner, or by the HIV-positive partner if the HIV-negative partner did not complete the question); PEP or PrEP was not reported by the HIV-negative partner during the period; the most recent plasma HIV-1 RNA viral load in the HIV-positive partner was measured to be less than 200 copies per mL and within the past 12 months at all points measured in the period; and follow-up occurred before April 30, 2018 (the censoring date). Couple-years of follow-up could be ineligible for one or more reasons; the choice of primary reason for ineligibility was prioritised in the following order: (1) PEP or PrEP used; (2) HIV-negative partner (or the HIV-positive partner if the HIV-negative partner did not reply) reported no condomless sex; (3) most recent viral load of HIV-positive partner more than 200 copies per mL; (4) data on sexual behaviour missing; (5) no viral load available in the past year for each day in the time period; and (6) no HIV test from the HIV-negative partner at the end of the time period or later in time. Two-sided 95% CIs for the incidence rate of transmission were calculated using exact Poisson methods. Missing data were not imputed and the analysis was performed only on the available data. Data were analysed using SAS version 9.4.

If an HIV-negative partner became HIV-positive, HIV-1 pol and env sequences were obtained from the seroconverted partner's HIV-1 RNA recovered from plasma and from the HIV-positive partner on virally suppressive ART's cellular HIV-1 DNA recovered from peripheral blood mononuclear cells. Pol and env sequences were generated by Sanger sequencing (on a ABI 3730xl DNA Analyzer, Thermo Fisher, Warrington, UK)complemented by deep sequencing of plasma HIV-1 RNA by Illumina (on a MiSeq, Illumina, Essex, UK) in a subset with available plasma samples.All sequencing testing was done at the University of Liverpool (Liverpool, UK). Maximum likelihood and Bayesian Markov chain Monte Carlo inferences and their relevant statistical support were determined with RAxML-HCP2 version 8 and MrBayes version 3.2.6, respectively, as previously described.

Sensitive testing of plasma HIV-1 RNA and Sanger sequencing of cellular HIV-1 DNA for the detection of drug resistance prior to starting first-line antiretroviral therapy with etravirine or efavirenz.

For the HIV-positive partner, ART regimen, CD4 cell count, and current and recent plasma HIV-1 RNA load were recorded on a clinical case report form at baseline and at each visit. The HIV-negative partner was asked to test for HIV every 6–12 months; a combined HIV antigen–antibody test was recommended to increase diagnostic sensitivity in early infection. Plasma HIV-1 RNA viral load was measured in the HIV-positive partner according to routine care every 6–12 months using the local diagnostic laboratory. Results were included in the case report forms and submitted after each partner visit by the study team to the study centre.

Study procedures have been described previously.Data were collected at baseline and then every 4–6 months during study visits. Detailed information was obtained at baseline and each follow-up visit through self-completed questionnaires on sociodemographics; self-reported adherence to ART; frequency and type of sexual activity between the partners (since last visit); symptoms and diagnoses of other sexually transmitted infections (STIs); use of PrEP or post-exposure prophylaxis (PEP); and injection drug use. HIV-negative partners were asked if they had condomless sex with anyone other than their HIV-positive partner in the study since their last visit and HIV serostatus of other partners if known.

The protocol,all informed consent forms, and participant information materials were submitted to and approved by the ethics committee (institutional review board [IRB] or independent ethics committee [IEC]) at each clinical site. Ethics approval was obtained in-country for all sites involved in the study. Additionally, any amendments to the study protocol were submitted and approved by each site's ethics committee (IRB or IEC).

From Sept 15, 2010, to July 31, 2017, we recruited serodifferent gay male couples from 75 clinical sites in 14 European countries. Participating clinic staff asked HIV-positive patients on ART if they had recent condomless sex with an HIV-negative partner and if they wished to take part in a transmission study. Serodifferent couples (HIV-positive men on ART with their HIV-negative male partner) were eligible to take part if both partners were aged 18 years or older; the partners reported having penetrative sex with each other without condoms in the month before enrolment; the HIV-positive partner expected to remain on ART; the partners expected to have sex together again in the coming months; and both partners agreed to take part. Partners signed separate informed consent forms, which included partner identification by name. Follow-up ended on April 30, 2018. Follow-up was stopped if the partnership ended, the couple moved away, or if either partner withdrew consent, but not for changes in use of condoms or ART.

The PARTNER study was an observational multicentre study of serodifferent couples who before enrolment were not always using condoms, and in which the HIV-positive partner was on ART. Phase 1 of the study recruited and followed up both heterosexual and gay serodifferent couples from Sept 15, 2010, to May 31, 2014.From June 1, 2014, to July 31, 2017, the second phase of the study recruited gay male serodifferent couples only. The methods for the PARTNER study and results of the first phase have been published previously.

Results

Between Sept 15, 2010, and July 31, 2017, 972 gay couples were recruited (477 couples during PARTNER1). By the end of follow-up on April 30, 2018, a total of 2072 couple-years of follow-up had been accrued (556 couple-years of follow-up during PARTNER1), with an estimated dropout rate of 25 per 100 couple-years of follow-up. Reasons for dropping out of the study were the couple broke up (213 [43%] of 499 couples), one or both partners moved away (33 [7%]), consent was withdrawn (54 [11%]), the 2-year study consent expired (21 [4%]), or the couple was no longer eligible (ten [2%]). The reason for dropping out of the study was not available for 168 (34%) couples. 479 couple-years of follow-up were ineligible for inclusion in the analysis for the following reasons: no condomless sex reported (153 [32%] of 479 couple-years of follow-up); use of PEP or PrEP (115 [24%]); HIV viral load data not available (86 [18%]); missing data on whether condomless sex was reported (91 [19%]); viral load in the HIV-positive partner more than 200 copies per mL (19 [4%]); or no HIV test available in the HIV-negative partner (15 [3%]).

1593 (77%) couple-years of follow-up were eligible and contributed by 782 couples, with 439 couple-years of follow-up contributed by 340 couples during PARTNER1. Unless otherwise stated, the following results focus on the 782 couples who provided eligible couple-years of follow-up. Median eligible years of follow-up per couple was 2·0 years (IQR 1·1–3·5). 1523 (96%) of the eligible couple-years of follow-up were during periods in which the most recent measure of plasma HIV-1 RNA in the HIV-positive partner was less than 50 copies per mL; the remaining 70 (4%) were during periods in which the most recent measure was between 50 and 200 copies per mL.

Baseline characteristics of the participants who contributed to eligible couple-years of follow-up are shown in table 1 . Median age was 38 years (IQR 31–45) in HIV-negative participants and 40 years (33–46) in HIV-positive partners. Three trans men were included, one HIV negative and two HIV positive. 19 (2%) of 782 HIV-positive and 33 (4%) of 782 HIV-negative men reported that they were bisexual. HIV-negative men reported having condomless sex with their HIV-positive partners for a median 1·0 years (IQR 0·4–2·9) before study enrolment.

Table 1 Baseline characteristics of couples eligible for the primary analysis HIV-positive partner (n=782) HIV-negative partner (n=782) Age (years) 40·0 (33·3–46·1) 37·6 (30·9–45·3) Ethnicity White 674/765 (88%) 686/767 (89%) Black 10/765 (1%) 9/767 (1%) Asian 14/765 (2%) 14/767 (2%) Other 67/765 (9%) 58/767 (8%) Education High school or less 143/762 (19%) 144/760 (19%) Vocational education 191/762 (25%) 176/760 (23%) College or university 428/762 (56%) 440/760 (58%) HIV acquisition route Heterosexual 2/762 (<1%) NA Homosexual 736/762 (97%) NA Shared needles or other injection equipment 0/762 NA Other 24/762 (3%) NA Years of condomless sex * Data missing for 63 HIV-positive partners and 64 HIV-negative partners. 1·0 (0·4–2·9) 1·0 (0·4–2·9) Years on ART † Data missing for 43 HIV-positive partners. 4·3 (1·8–9·3) NA Self-reported adherence ≥90% 739/753 (98%) NA <90% 14/753 (2%) NA Missed ART for more than 4 consecutive days Yes 15/762 (2%) NA No 747/762 (98%) NA Informed their partner if they missed doses of ART No 26/765 (3%) NA Yes 316/765 (41%) NA Did not miss doses 423/765 (55%) NA Correctly self-reported HIV load (whether undetectable or not) Yes 698/747 (93%) NA No 49/747 (7%) NA Undetectable viral load (measured, copies per mL) <50 754/781 (97%) NA ≥50 27/781 (3%) NA Undetectable viral load (measured, copies per mL) <200 774/781 (99%) NA ≥200 7/781 (<1%) NA CD4 count (cells per μL) >350 730/781 (93%) NA ≤350 51/781 (7%) NA Data are median (IQR) or n/N (%). NA=not applicable. ART=antiretroviral therapy. Denominators for percentages are all participants in that group who contributed to eligible couple-years of follow-up and provided a response to that question (missing data are excluded).

At baseline, HIV-positive partners had been on ART for a median of 4·3 years (IQR 1·8–9·3). Self-reported adherence to ART was high, with 739 (98%) of 753 HIV-positive partners reporting adherence of 90% or more at study entry. 698 [93%] of 747 HIV-positive partners correctly self-reported at baseline whether their viral load was undetectable or not. This was an underestimate by the HIV-positive participants: 97% had undetectable viral load (<50 copies per mL) and 99% had viral load of less than 200 copies per mL. 730 [93%] of 781 HIV-positive partners had a CD4 count of more than 350 cells per μL at baseline.

During all couple-years of follow-up, very few (37 [5%] of 779) of the HIV-positive partners reported that they missed ART for more than four consecutive days. For 1461 (92%) of 1593 eligible couple-years of follow-up, adherence was more than 90% (not reported for 96 [6%] couple-years of follow-up) according to the HIV-positive partner. Most HIV-positive partners were on ART regimens containing three or more drugs (1470 [92%] couple-years of follow-up), with fewer HIV-positive partners taking regimens containing two drugs (73 [5%] couple-years of follow-up), or ART monotherapy (34 [2%] couple-years of follow-up). For the remaining 1% (16 couple-years of follow-up), the HIV-positive partners were either in a blinded clinical trial group or the ART regimen was unknown. For a quarter (396 [25%]) of eligible couple-years of follow-up, the HIV-positive partners were taking protease-inhibitor based regimens, for 47% (754 couple-years of follow-up) they were taking non-nucleoside reverse transcriptase inhibitor-based regimens, for 26% (408 couple-years of follow-up) they were taking integrase inhibitors, and for the remaining 2% (35 couple-years of follow-up) they were taking other or not reported regimens.

During follow-up ( table 2 ), 185 (24%) of 779 HIV-negative men and 214 (27%) of 779 HIV-positive men reported an STI since their last visit. Couples reported having condomless sex 6090 times during eligible periods when an STI was present. 288 (37%) of 777 HIV-negative partners reported condomless sex with other partners. Few HIV-negative partners (28 [4%] of 775) reported injecting drugs during follow-up. In total, couples reported having condomless anal sex approximately 76 088 times during eligible couple-years of follow-up ( figure 1 ). The median number of times couples had condomless sex was 43 times per year (IQR 19–75). Condomless sex was reported 2–10 times per 4-month period in 657 (41%) of 1593 eligible couple-years of follow-up, 21–40 times per 4-month period in 408 (26%) eligible couple-years of follow-up, and between 11 and 20 times per 4-month period in 332 (21%) eligible couple-years of follow-up ( appendix ).

Table 2 Characteristics during all follow-up of couples eligible for the primary analysis HIV-positive partner (n=782) HIV-negative partner (n=782) Time in the study (years) 2·0 (1·1–3·5) 2·0 (1·1–3·5) STIs * Participants who reported an STI (excluding HIV) since the last visit were asked whether it was syphilis, gonorrhoea, chlamydia, acute genital herpes, chronic genital herpes, LGV, or other. Participants who replied “yes” to the question “Since your last visit, have you had an STI?” but did not reply to the question “If yes, which STI?” were categorised as “not specified”. 214/779 (27%) 185/779 (24%) Syphilis 69/779 (9%) 54/779 (7%) Gonorrhoea 85/779 (11%) 84/779 (11%) Chlamydia 79/779 (10%) 66/779 (8%) Herpes 10/779 (1%) 10/779 (1%) Chronic herpes 7/779 (1%) 5/779 (1%) Warts 22/779 (3%) 20/779 (3%) LGV 9/779 (1%) 4/779 (1%) Other STI 24/779 (3%) 23/779 (3%) Not specified 4/779 (1%) 3/779 (<1%) Condomless sex with other partners Yes NA 288/777 (37%) No NA 489/777 (63%) Condomless sex with other HIV-positive partners † Only participants who reported condomless sex with other partners were asked this question. For this variable, missing is treated as “no” and the denominator to calculate the percentages is the number of participants who answered the question on whether they had “condomless sex with other partners” (n=777). Yes NA 249/777 (32%) No NA 528/777 (68%) Condomless sex acts ‡ Only sex acts within couples are included. 41·3 (17·6–72·7) 43·4 (19·2–75·1) Total number of condomless sex acts during eligible CYFU ‡ Only sex acts within couples are included. 73 674 76 088 Missed ART for more than 4 consecutive days Yes 37/779 (5%) NA No 742/779 (95%) NA Injected non-prescription drugs Yes 42/779 (5%) 28/775 (4%) No 737/779 (95%) 747/775 (96%) CYFU with reported frequency of condomless sex per month of § The denominator is the total group-specific eligible CYFU (1593 CYFU). Note numerators and percentages do not add up to 1593 and 100%, respectively, because of rounding. Less than once 335/1593 (21%) 312/1593 (20%) 1–2 times 222/1593 (14%) 236/1593 (15%) 3–4 times 310/1593 (19%) 329/1593 (21%) 5–8 times 434/1593 (27%) 439/1593 (28%) More than 8 times 227/1593 (14%) 240/1593 (15%) Not reported or missing 64/1593 (4%) 38/1593 (2%) Data are median (IQR) or n/N (%), unless othewise specified. Denominators for percentages are all participants in that group who contributed to eligible couple-years of follow-up and provided a response to that question (missing data are excluded), unless otherwise specified. Missing data are less than 1% for all variables. STIs=sexually transmitted infections. LGV=lymphogranuloma venereum. NA=not applicable. CYFU=couple-years of follow-up. ART=antiretroviral therapy.

Figure 1 Rate of within-couple HIV transmission through condomless sex according to sexual behaviour reported by the HIV-negative partner Show full caption STI=sexually transmitted infection. NA=not applicable. *Estimated using the exact Poisson method. †Numerator is the number of HIV-negative men within the eligible couples ever reporting that specific sexual act and denominator is the group-specific number of HIV-negative participants who contributed eligible couple-years of follow-up. ‡Refers to STIs (excluding HIV) self-reported by the HIV-negative partner.

Figure 1 shows data on prevalence of the types of condomless penetrative sex (with the HIV-positive partner) reported by the HIV-negative partner. By definition, couples contributing eligible couple-years of follow-up reported anal sex without condoms during follow-up. Overall, 577 (75%) of 773 HIV-negative partners reported that they had receptive anal sex without ejaculation during follow-up, 436 (56%) of 776 reported receptive anal sex with their partner ejaculating inside, and 709 (91%) of 777 reported insertive anal sex.

15 of the initially HIV-negative partners became HIV-1 positive during eligible follow-up, but there were no within-couple phylogenetically linked transmissions. 13 of the 15 individuals provided information about their presumed source of HIV infection, of whom ten (77%) reported recent condomless sex with men other than their study partner. Samples collected from the two partners of each of these 15 couples for sequencing were a median of 0 months apart (IQR 0·0–5·9). Viral sequences were recovered successfully from all couples (15 [100%] of 15 couples for pol genes and 13 (87%) of 15 for env genes). All new infections were phylogenetically unrelated to the initially HIV-positive partner's virus ( figure 2 and appendix ). Viral haplotypes derived from deep sequencing data of plasma samples from HIV-negative partners from five (33%) of the 15 couples confirmed the lack of linkage, since all viral haplotypes in the seroconverter samples were phylogenetically unrelated to the virus from their partners. All 15 partners who were the initially HIV-positive partner had subtype B infection according to pol gene subtyping; six of the 15 seroconverting partners acquired non-B infections (subtypes C, A1, CRF29_BF, CRF60_BC, and two partners acquired CRF14_BG infections, respectively).

Figure 2 Phylogenetic tree of pol and env sequences from nine couples with subtype B infection Show full caption 13 Beloukas A

Magiorkinis E

Magiorkinis G

et al. Assessment of phylogenetic sensitivity for reconstructing HIV-1 epidemiological relationships. Bayesian Markov Chain Monte-Carlo inference (012313+I+G+F). Branch length is proportional to the genetic distance and line weight is proportional to the posterior probability. (A) Partners' (initially HIV-positive partners and seroconverters) sequences are in blue and found phylogenetically unlinked to viruses recovered from their putative transmitters, with a median pairwise genetic distance of 0·069 (IQR 0·057–0·076) and pairwise genetic distances consistently greater than 0·040. Positive control sequences comprised replicate sequences from study partners and sequences from confirmed transmission pairs obtained in a separate study.The positive control sequences show pairwise genetic distance 0·004 (IQR <0·000 to 0·007) and always closely linked on monophyletic clusters with posterior probabilities more than 0·98 (red and orange clusters in the phylogenetic tree). Control sequences comprised the ten closest sequences identified through BLAST searches of GenBank. (B) Partners' (initially HIV-positive partners and seroconverters) sequences are in blue and found phylogenetically unlinked to viruses recovered from their putative transmitters, with a median pairwise genetic distance of 0·14 (IQR 0·125–0·169). Positive control sequences comprised replicate sequences from study partners (in red). The positive control sequences show pairwise genetic distance 0·001 (IQR <0·001 to 0·014) and always linked on monophyletic clusters with posterior probabilities equal to 1·00 (red clusters in the phylogenetic tree). Control sequences comprised the ten closest sequences identified through BLAST searches of GenBank.

8 Rodger AJ

Cambiano V

Bruun T

et al. Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy. With no linked transmissions, the estimated rate for transmission through condomless anal sex when the positive partner on ART had HIV viral load less than 200 copies per mL was zero, with an upper 95% CI limit of 0·23 per 100 couple-years of follow-up (equivalent to one transmission per 435 years of condomless sex). Figure 1 reports the rates of within-couple HIV transmission per 100 eligible couple-years of follow-up by sexual behaviour reported by the HIV-negative partner. For receptive anal sex with ejaculation the upper 95% CI limit was 0·57 per 100 couple-years of follow-up (equivalent to one transmission per 175 years of condomless sex). Figure 3 gives the upper bounds of the 95% CI around the estimate of zero transmissions for gay men and heterosexual couples achieved by the end of PARTNER1and for gay men by the end of PARTNER2.

Figure 3 8 Rodger AJ

Cambiano V

Bruun T

et al. Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy. Upper 95% CI limit around estimated rate of zero HIV transmissions through penetrative sex (vaginal or anal) at the end of PARTNER1

There were fewer eligible couple-years of follow-up during periods when the HIV-positive partner (135 couple-years of follow-up) or the HIV-negative partner (116 couple-years of follow-up) reported an STI, but no linked transmissions were reported. The upper 95% CI limit to the transmission estimate for periods with an STI in the HIV-negative partner was 3·17 per 100 couple-years of follow-up. Only 8 couple-years of follow-up of condomless sex were reported when the HIV-positive partner was in the first 6 months of taking ART.

Six additional seroconversions in HIV-negative partners took place outside eligible couple-years of follow-up. Reasons for the ineligibility of the couple-years in which these seroconversions occurred were no questionnaire containing sexual behaviour at the end of the period by the HIV-negative or HIV-positive partner (n=3); HIV-negative partner reported no condomless sex with the HIV-positive partner (n=1); use of PEP reported during the period when the infections occurred (n=1); and no HIV viral load measurement for the HIV-positive partner in the past year (n=1). The six newly infected partners were last seen 2 months, 6 months (n=2), 9 months, 13 months, and 16 months before seroconversion was recorded, respectively. Phylogenetic analysis showed that these transmissions were not linked to the HIV-positive partner on virally suppressive ART.

19·3 couple-years of follow-up were not eligible because of viral load in the HIV-positive partner being higher than 200 copies per mL for at least 1 day during the period (range 202–170 000 copies per mL), but all other criteria were met. During couple-years of follow-up with viral load higher than 200 copies per mL, people reported having condomless sex a total of 810 times with zero phylogenetically linked transmissions. For the majority of these days, the most recent viral load in the HIV-positive partner was less than 200 copies per mL (12·3 couple-years of follow-up, estimated 513 sex acts), for 4·5 couple-years of follow-up the most recent viral load was between 200 and 1000 copies per mL (estimated 180 sex acts), and only for a minority of days the most recent viral load was higher than 100 000 copies per mL (0·23 couple-years of follow-up, estimated 31 sex acts).

[END]
---
[1] Url: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)30418-0/fulltext

Published and (C) by Our World in Data
Content appears here under this condition or license: Creative Commons BY.

via Magical.Fish Gopher News Feeds:
gopher://magical.fish/1/feeds/news/ourworldindata/